Glyconics, which is part of the Deepbridge Life Sciences EIS portfolio, has secured £1.5 million in an Enterprise Investment Scheme (EIS) funding round ahead of a series A round next year. 

Deepbridge Capital has deployed over £50 million of capital into UK life sciences companies.

The Deepbridge Life Sciences EIS was launched in 2017 as our first life sciences focused EIS fund, providing private investors with access to a portfolio of early-stage investee companies across the biopharmaceutical, biotechnology, medical technology and digital healthcare sectors.

One of Deepbridge's Technology Growth EIS Companies HeadBox, has finalised a £2 million fundraise led by Deepbridge Capital. This round has taken the total funding to £13.2 million.

Deepbridge Capital has now exceeded £200 million of funds deployed across is EIS and Estate Planning Service funds, with a current Net Asset Value (NAV) of over £250 million.

Deepbridge Capital has, to date, invested in 71 companies across the UK with Enterprise Investment Scheme (EIS) funding, a further 63 companies at the Seed EIS stage, with three profitable exits. Deepbridge Capital launched its first EIS Fund in the 2013/14 tax year specialising in providing venture capital to early-stage technology, life sciences and renewable energy companies.

Deepbridge is pleased to announce that we have been awarded the ‘Spirit of EIS’ Award at the 2021 EISA Awards, which took place in The Cholmondeley Room at The House of Lords on the 7th October.

Our Deepbridge Renewable Energy Enterprise Investment Scheme (EIS) fund has announced an exit for its investors.

Deepbridge Renewable Energy Limited, a trading company within the EIS Fund which constructed and managed wind turbines in Northern Ireland, has been sold to a private buyer, providing a 1.146x return for investors, excluding tax reliefs available under the Enterprise Investment Scheme.

Earlier this month Deepbridge Capital, in partnership with GBI Magazine undertook a research survey of financial advisors and paraplanners focused on the Enterprise Investment Scheme (EIS). 

There is an increasing interest in using EIS funds as part of their planning and creating a balanced portfolio. Over 52% of respondents expect their use of EIS to increase over the next two years and 90% of advisers are considering EIS funds for their clients. 

Algaecytes GmbH, a wholly owned subsidiary of Algaecytes Ltd, which is part of the Deepbridge Technology Growth EIS portfolio, has announced that the City Council of Dessau-Rosslau, in the State of Saxony-Anhalt in Germany, unanimously agreed to sell property in the industrial and commercial area Flugplatz Dessau to AlgaeCytes Germany GmbH.